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SUMMARY 
Background: Persistent hyperglycaemia in diabetes mellitus causes coagulopathies due to glycation of haemoglo-
bin, prothrombin, fibrinogen and other proteins involved in the clotting mechanism. Shortened activated partial 
thromboplastin time (APTT) and prothrombin time (PT) reflect hypercoagulable state, which is associated with an 
increased thrombotic risk and adverse cardiovascular effects.  This study assessed the coagulation profile of type 2 
diabetes mellitus (T2DM) clients at a municipal hospital in Ghana. 
Methods: A hospital-based case-control study was conducted from January to April 2015 at the Agona Swedru Mu-
nicipal Hospital. Sixty (60) persons with T2DM and 40 without were recruited and screened using appropriate pro-
tocols. Blood samples were collected for coagulation and biochemical tests. Demographic and clinical information 
were collected using pre-tested questionnaire. Data was analyzed with GraphPad Prism version 5. 
Results: APTT and PT were significantly shorter among patients with T2DM compared to those without (20.88 ± 
5.19 v 31.23 ± 5.41, P=0.0001; and 11.03 ± 2.06sec v 14.46 ± 1.86, P=0.0001 respectively). INR was decreased 
among patients with T2DM compared to those without (0.83 ± 0.18 v 1.13 ± 0.17, P=0.0001). No significant differ-
ence was found in platelet count between T2DM and non-diabetics (179.85 ± 66.15×103 /mm3 v 168.55 ± 35.77×103 
/mm3, P=0.326). Serum magnesium was lower among the T2DM patients compared to the non-diabetics, while se-
rum ionized calcium was significantly higher among the T2DM patients (P<0.05). 
Conclusion: Clients with T2DM may have a high coagulation risk evidenced by shortened APTT, PT and a high 
ionized calcium compared with controls. 
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INTRODUCTION 
Diabetes mellitus (DM) is a group of metabolic diseases 
characterized by increased blood glucose, which results 
primarily from defects in insulin secretion, insulin ac-
tion, or both and symptoms include polyuria, polydipsia 
and polyphagia.1 Prevalence of DM worldwide is 8.5% 
with 6.3% prevalence in Ghana.2 The prevalence in 
Ghana has recently been estimated to be 3% of the 
country’s general populace.3 
Metabolic disturbances that commonly occur in patients 
with type 2 diabetes are atherogenic dyslipidaemia, hy-
pertension, glucose intolerance, and a prothrombotic 
state.4,5 This prothrombotic state is a more recently rec-
ognized component of the metabolic syndrome; people 
with metabolic syndrome exhibit a pattern of coagula-
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The underlying mechanisms for increased thrombosis 
risk in diabetes are complex and involve multiple path-
ways.  
 
Subjects with diabetes have premature atherosclerosis 
and more extensive vascular disease, predisposing them 
to plaque rupture and thrombus formation. In addition, 
these individuals have increased thrombotic tendency 
due to platelet hyper-reactivity and increased activation 
of prothrombotic coagulation factors coupled with de-
creased fibrinolysis.  
 
The prothrombotic state is characterized by increased 
fibrinogen levels7, increased plasminogen activator in-
hibitor (PAI)-18, and different abnormalities in platelet 
function.6 Studies have reported contrasting coagulation 
profiles among diabetes patients. Acang and Jalil9 re-
ported shorter prothrombin times (PTs) and activated 
partial thromboplastin times (APTTs) in patients with 
diabetes. Conversely, Collier et al10 found normal PTs 
in patients with type 2 diabetes. Erem et al11 reported 
normal PTs and APTTs in diabetes.  
 
Although sub-Saharan Africa has the highest burden of 
diabetes, many studies have not been done in this region 
to explore the impact of diabetes mellitus on coagula-
tion profile.  We therefore sought to assess the coagula-
tion profile of persons with type 2 Diabetes Mellitus 
(T2DM) in a district hospital in Ghana. 
 
METHODS 
Study Design/ Study Site 
This was a hospital-based case control study conducted 
from January to April 2015 at the Agona Swedru Mu-
nicipal Hospital (ASMH) in the Central Region of Gha-
na. ASMH is located in Agona West District with a total 
projected population of 403,943. The hospital is the 
largest health facility in the district and serves as the 
main referral facility in the district and its neighbouring 
villages. As per the records of the OPD unit, the total 
number of diabetes patient who visit the hospital is 651 
per year; 500 of these are T2DM patients.  
 
Study Population 
A total of 100 participants comprising 60 T2DM pa-
tients and 40 non-Diabetics attending the out-patient 
department of ASMH in Agona Swedru were recruited 
for the study. Persons with type 1 Diabetes Mellitus and 




The study had approval from the University of Cape 
Coast Institutional Review Board (UCCIRB) and the 
hospital authorities.  
A written consent was sought from participants after a 
thorough explanation of the study protocols. Results and 
records were strictly kept confidential.  
 
Administration of Questionnaire  
A well-structured questionnaire was used to obtain in-
formation on demographic variables such as age, sex, 
occupation, gender; and clinical history of each partici-
pant 
 
Blood Pressure Measurement 
Trained personnel measured the blood pressure using a 
mercury sphygmomanometer and a stethoscope. All 
measurements were in accordance with recommenda-
tions of the American Heart Association.12 Hypertension 
was graded as normal when the systolic blood pressure                              
(SBP) was <120 mm Hg and diastolic blood pressure 
(DBP) was <80 mm Hg.13 
  
Anthropometrics 
The height (to the nearest metre) using a wall-mounted 
graduated ruler and weight (to the nearest 0.1 kg) in 
light clothing, with a weighing balance (Seca, Hamburg, 
Deutschland) were measured. The body mass index 
(BMI) was then calculated as the ratio of the weight 
(kg) and the square of the height (m2). BMI was catego-
rized as: <18.5 (underweight); 18.5 to 24.5 (normal 
weight); 25 to 29.5 (overweight); and ≥30 (obese).  
 
The hip circumference at the widest portion of the but-
tocks and waist circumference midway between the 
inferior margin of the last palpable rib and the suprailiac 
crest (both to the nearest 0.1 cm) were also measured 
using a measuring tape. The waist-hip ratio was calcu-
lated from the waist circumference/ hip circumference. 
 
Blood sample collection 
From each consented participant, 10ml of venous blood 
(fasting) was collected of which 5ml was put into fluo-
ride oxalate tube, 1.4ml into a tube containing EDTA 
and 3.6ml into a plastic buffered tri-sodium citrate tube 
containing 380 µl of 3.2% buffered tri-sodium citrate. 
The sample in 3.2% buffered tri-sodium citrate tube and 
fluoride oxalate tube were centrifuged at 1500 rpm for 
15 minutes and the plasma separated for PT/APTT and 
plasma glucose measurements respectively. 
 
Biochemical Tests 
Fasting plasma glucose was estimated using the glucose 
oxidase/peroxidase method.14 Serum albumin, total cal-
cium and magnesium were estimated using an autoana-
lyser (Mindray, China). Ionized calcium (Cal-I) was 
then calculated using the formula; Cal-I mmol/L =0.25 
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APTT, PT, and platelet estimation 
Platelet count was estimated using Sysmex Haematolo-
gy Analyser (Sysmex XT-2000i, Kobo, Japan). Pro-
thrombin time and activated partial thromboplastin time 
were estimated on venous blood anticoagulated with 
sodium citrate. INR was calculated using the formula: 
INR = (PT patient/GMNPT)IS, where GMNPT is geo-
metric mean normal prothrombin time from 20 normal 
donors and ISI is international sensitivity index.  
 
Statistical Analysis 
Data was entered into Microsoft Excel and statistical 
analysis was carried out using Statistical Package for 
Social Sciences (SPSS) version 17.0 for Microsoft Win-
dows, 13th students’ edition. Continuous variables were 
reported using mean and standard deviation and Chi 
square model used to analyze categorical variables. 
P<0.05 was considered statistically significant 
 
RESULTS 
Table 1 Demographic, anthropometric, clinical charac-
teristics and biochemical profile of persons with T2DM 
(Cases) and non-diabetics (Control) 
Variable Subjects Control p-value 
 
(n= 60) (n = 40) 




Male 24 (40.0) 17 (42.5) 




Unemployed 7 (11.7) 2 (5.0) 
 Informal 41 (68.3) 14 (35.0) 
 Formal 12 (20.0) 24 (60.0) 
 SBP (mmHg) 146.28 ± 31.91 118.75 ± 13.99 <0.0001 
DBP (mmHg) 80.28 ± 20.36 76.50 ± 9.21 0.274 
FBG (mmol/L) 11.84 ± 6.25 4.55 ± 0.41 <0.0001 
WHR (cm) 0.94 ± 0.10 0.83 ± 0.10 <0.0001 
BMI (Kg/m2) 21.48 ± 4.41 20.67 ± 4.60 0.381 
Coagulation Profile 
PLT x 103/mm3 179.85 ± 66.15 168.55 ± 35.77 0.326 
APTT 20.88 ± 5.19 31.23 ± 5.41 <0.0001 
PT 11.03 ± 2.06 14.46 ± 1.86 <0.0001 
INR 0.83 ± 0.18 1.13 ± 0.17 <0.0001 
Albumin, g/L  34.96 ± 3.89 37.73 ± 2.88 < 0.0001 
Magnesium, 
mmol/L 0.75 ± 0.12 0.91 ± 0.16 < 0.0001 
Calcium-Total, 
mmol/L 2.50 ± 0.28 2.42 ± 0.20 0.110 
Calcium-
ionized, mmol/L 1.36 ± 0.22 1.27 ± 0.11 0.024 
  
SBP=Systolic Blood Pressure, DBP=Diastolic Blood Pressure, 
FBG=Fasting Blood Glucose PLT=Platelet, WHR=Waist Hip Ratio, 
BMI=Body Mass Index, APTT=Activated Partial Thromboplastin, 
PT=Prothrombin Time 
 
The mean age of the type 2 Diabetes Mellitus patients 
was 55.9 ± 14.1 years, with majority of them in their 
sixth decade of life.  
There was no significant difference in the platelet count 
and total calcium level of the type 2 diabetes patients 
and the non-diabetics. 
 
Table 2 Demographics and clinical characteristics of 
persons with T2DM stratified by gender  




(n = 24) (n = 36) 




Unemployed 3 (42.9) 4 (57.1) 
 Informal 14 (34.1) 27 (65.9) 
 Formal 7 (58.3) 5 (41.7) 
 Duration of 
drug use 
(years) 4.46 ± 3.09 3.89 ± 2.31 0.579 
Clinical Char-
acteristics 
   Polyuria 
  
0.785 
Yes 20 (40.8) 29 (59.2) 
 No 4 (36.4) 7 (63.6) 
 Weight Loss 
  
0.645 
Yes 16 (38.1) 26 (61.9) 
 No 8 (44.4) 10 (55.6) 
 Blurred Vision 
  
0.598 
Yes 20 (41.7) 28 (58.3) 





Yes 16 (37.2) 27 (62.8) 
 No 8 (47.1) 9 (52.9) 
  
However, PT, APTT and INR were significantly de-
creased among persons with type 2 diabetes compared 
to non-diabetics. Serum albumin and magnesium were 
significantly lower among the type 2 diabetes patients 
compared to the non-diabetics; while serum ionized 
calcium was significantly higher among the type 2 pa-
tients (Table 1). 
 
Table 2 presents the demographics and clinical charac-
teristics of the diabetic patients stratified by gender. 
Informal occupation and unemployment were more in 
females than in males (65.9% v 34.1%; and 57.1% v 
42.9% respectively).  
 
There was no significant difference in duration of drug 
use among males and females (P=0.579). Polyuria 
(59.2), weight loss (61.9%) impaired wound healing 
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ondary conditions (62.8%) were higher in females than 
in males. 
 
Table 3 shows coagulation profile and anthropometric 
measures of diabetics on therapy (Cases) stratified by 
gender. Apart from PT and FBG, there was no signifi-
cant difference in the coagulation and biochemical pro-
file of the type 2 diabetes patients with respect to gen-
der. WHR and BMI were associated with gender 
(P<0.05). 
 
Table 3 Biochemical profile and anthropometric 
measures of persons with T2DM stratified by gender 
Variable Male Female P-value 
 
(n = 24) (n = 36) 
 Coagulation Profile 
   PLT x 103/mm3 187.96 ± 73.88 174.44 ± 60.95 0.443 
APTT 21.67 ± 6.01 20.36 ± 4.59 0.345 
PT 11.54 ± 2.35 10.69 ± 1.81 0.119 
INR 0.88 ± 0.20 0.81 ± 0.16 0.160 
Coagulation Profile 
n (%) 
   PLT  
  
0.280 
< 150 6 (30.0) 14 (70.0) 
 150-450 17 (43.6) 22 (56.4) 




<25 17 (37.0) 29 (63.0) 




< 10 3 (20.0) 12 (80.0) 
 10-14 16 (40.0) 24 (60.0) 
 >14 5 (100) 0 (0.0) 
 INR 0.88 ± 0.20  0.81 ± 0.16 0.160 
Albumin, g/L  34.65 ± 4.25 35.18 ± 3.68 0.621 
Magnesium, mmol/L 0.73 ± 0.11 0.76 ± 0.12 0.417 
Calcium-Total, 
mmol/L 2.49 ± 0.31 2.51 ± 0.26 0.802 
Calcium-ionized, 
mmol/L 1.39 ± 0.31 1.34 ± 0.14 0.435 
SBP (mmHg) 146.67 ± 34.60 146.03 ± 30.49 0.940 
DBP (mmHg) 83.04 ± 27.37 78.44 ± 14.07 0.396 
FBG (mmol/L) 14.21 ± 7.83 10.27 ± 4.39 0.015 
WHR (cm) 0.93 ± 0.06 0.94 ± 0.11 0.900 
BMI (Kg/m2) 19.60 ± 3.99 22.73 ± 4.27 0.006 
 
We also used multivariate logistic regression analysis to 
investigate factors that could predict coagulation ab-
normality in T2DM patients (Table 4).  
 
Our study showed that age, waist-hip ratio (WHR), 
body mass index (BMI), duration of drug use, and the 
presence of secondary conditions do not significantly 
predict low PT, APTT or platelet count. 
 
DISCUSSION 
Prothrombotic state is a more recently recognized com-
ponent of the metabolic syndrome. People with the met-
abolic syndrome, as in T2DM, exhibit a pattern of co-
agulation factors that promote thrombosis or retard 
thrombolysis.5  
This study sought to measure clotting profile and plate-
let count in patients with T2DM. Our findings showed 
significantly shorter APTT and PT, with concurrent 
significantly higher ionized calcium among patients 
with T2DM compared to the non-Diabetics. These find-
ings demonstrate an increased predisposition to throm-
botic events in T2DM patients compared to non-
Diabetic controls.  
 
Our findings are consistent with other previously pub-
lished reports that found shortened APTT and PT in 
diabetes patients compared to non-diabetic controls.9,16 
In an epidemiological study that investigated the associ-
ation between plasma glucose levels and APTT in type 
2 diabetes mellitus patients, Lippi et al.,16 also found 
shortened APTT in diabetes patients. However, a simi-
lar case-control study by Madan et al., 17 did not find 
any significant difference in APTT among type 2 dia-
betics and healthy controls. The Medan et al., study 
however recruited a relatively lower sample size in the 
control group (30 vs 40 in this study) which might have 
accounted for this variance in addition to the differences 
in the population demographics. Similarly, PT and INR 
were shorter among the type 2 Diabetics compared to 
the controls.  
 
This study also corroborates the shorter APTT recorded 
by Acang and Jalil 9 but is inconsistent with the findings 
of Zhao et al., 18 who obtained insignificant shortened 
PT value among patients with type 2 diabetes in a case-
control study in Zhejiang University in China. Madan et 
al., 17 also did not find any difference in PT among type 
2 Diabetics. The differences in coagulation test results 
observed could be due to differences in sample size 
used, race and geographical locations. 
 
Ionized calcium is a critical component of the coagula-
tion cascade in man and therefore any derangement in 
its levels may have adverse consequences on the coagu-
lation profile. Previous studies have reported abnormal 
calcium levels among patients with diabetes. 19-21 This is 
supported by the significantly higher serum ionized cal-
cium among type 2 diabetes patients in our study.  
 
Variation with regard to calcium and Na+/K+-ATPase 
activities and abnormal hormonal regulation of intracel-
lular calcium has been implicated in the abnormal calci-
um levels reported in T2DM. 22 As ionized calcium rep-
resent the biologically active form of calcium readily 
available for physiological functions, its significant in-
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Table 4 Regression analyses of factors associated with decrease in measures of coagulation abnormality 












Female 1.91 (0.61-5.98) 0.267 1.71 (0.51-5.70) 0.386 3.50 (0.87-14.11) 0.078 
Age group  
< 30* 1 
 
1 
   
30-39 - - 0.50 (0.02-11.08) 0.661 0.2 (-) - 
40-49 0.08 (0.00-2.05) 0.128 
  
1.50 (0.09-25.39) 0.779 
50-59 0.18 (0.01-2.32) 0.187 1.42 (0.11-18.60) 0.791 0.42 (0.03-5.85) 0.519 
60-69 0.50 (0.04-7.10) 0.609 2.50 (0.15-42.80) 0.527 2.00 (0.14-28.42) 0.609 








Overweight 0.54 (0.15-1.97) 0.346 0.89 (0.19-4.13) 0.885 0.78 (0.19-3.27) 0.734 
Obese 2.57 (0.56-11.72) 0.224 0.30 (0.06-1.63) 0.164 2.32 (0.47-11.55) 0.303 
BMI 
 







Overweight 0.63 (0.14-2.88) 0.554 1.30 (0.22-7.61) 0.768 2.25 (0.54-9.37) 0.267 
Obese 0.09 (0.000) - 2.84 - 0.03 (0.000) - 
2oCondition 






 OR=Odds Ratio 
 
Platelet function in haemostasis may be affected by 
quality and/or quantity of the platelets. Vinik et al.  23 
observed functional anomalies in platelets in type 2 dia-
betes suggesting that any impact of diabetes on platelets 
may be qualitative but not quantitative. In line with this 
we found no significant difference in platelet count be-
tween diabetes and non-diabetes controls. This agrees 
with Madan et al., 17 who also reported non-significant 
variation in platelet count between diabetes patients 
with or without complications and healthy controls.  
 
In addition, the lower serum magnesium found among 
type 2 diabetes patients compared to non-diabetics is in 
line with the findings of Wälti et al., 24 who demonstrat-
ed low magnesium status in type 2 Diabetics in the Zur-






Magnesium (Mg) depletion has an effect on glucose 
homeostasis and insulin sensitivity in diabetic patients 25 
as well as on the evolution of complications such as 
thrombosis and hypertension.25  
 
Other studies have shown inhibitory effects of Mg on 
platelet function through various suggested mechanisms 
such as production of prostacyclin 26 or altered inositol 
phosphate generation.27 Therefore our finding of signifi-
cantly reduced Mg levels in T2DM supports studies 
from others who suggested that oral Mg supplementa-
tion may be beneficial in preventing the platelet hyper-






                                                                                                                                                                               
www.ghanamedj.org  Volume 51 Number 3 September 2017 106 
Previously, others have suggested that individuals with 
T2DM have increased thrombotic tendency due to plate-
let hyper-reactivity as well as increased activation of 
prothrombotic coagulation factors coupled with de-
creased fibrinolysis.29  
This is supported by the finding of decreased PT and 
APTT in our study together with the significantly re-
duced Mg levels in our diabetes subjects.  
 
This thrombotic predisposition may be compounded by 
the significantly elevated ionized calcium (Factor IV) 
among the type 2 diabetes patients compared to the 
healthy controls. However, further studies that possibly 
employ animal models are recommended to ascertain 
exact pathophysiological role of ionized calcium in the-
se patients.  
 
Additionally, we recommend a similar study to be un-
dertaken that will compare the coagulopathy in T2DM 
patients with poor glycaemic control and those with 
tightly controlled glycaemia to inform clinicians in the 
management of these patients. Our study is limited by 
the small sample size and inability to perform specific 
factor assays as well as platelet function assay. 
 
CONCLUSION 
A shorter APTT and PT were found among patients 
with T2DM compared to the non-Diabetics. There was 
no significant difference in platelet count between type 
2 diabetic patients and non-diabetics, with serum ion-
ized calcium being higher among the type 2 Diabetic 
patients. This indicates higher risk of thrombosis in 
T2DM patients. Coagulation profile must be considered 
as a routine test among diabetes patients during their 
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